You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Recombinant human CC10 protein for treatment and prevention of chronic lung allograft dysfunction

    SBC: APC BIO INNOVATIONS INC            Topic: NHLBI

    Abstract Over 5,000 lung transplants (LTx) are performed in the US each year to save the lives of patients in respiratory failure due to COPD, idiopathic pulmonary fibrosis, cystic fibrosis, pulmonary hypertension, and other terminal lung conditions. The vast majority of LTx, long-term survival is significantly limited by chronic lung allograft dysfunction (CLAD) with a median survival of 6 years ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Conditional male lethal Anopheles stephensi line for the efficient manufacture of malaria vaccines

    SBC: SANARIA INC.            Topic: NIAID

    Project Abstract In 2020 malaria cases (241M) and deaths (627,000) reached the highest since 2012 emphasizing the urgent need for new tools for prevention, control, and elimination of this disease. Sanaria’s Plasmodium falciparum (Pf) sporozoite (SPZ) Vaccine, composed of radiation attenuated PfSPZ administered by intravenous injection, assessed in 1740 subjects aged 5 months to 61 years in 6 co ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. A Novel Immunological-Directed Synthetic Biology-Based Drug for the Treatment of Multiple Sclerosis

    SBC: Rise Therapeutics, LLC            Topic: NIAID

    Project Summary Our goal is to develop a novel, immunological-directed synthetic biology-based therapeutic for the treatment of Multiple Sclerosis (MS). MS is a devastating characterized by an exacerbated immune response that destroy myelin. This disease affects many important aspects of a patient's life, including emotional well-being, quality of life, working ability, and social interactions. In ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Metalloenzyme binding affinity prediction with VM2

    SBC: VERACHEM LLC            Topic: 400

    Project summary: It is estimated that 40 to 50% of known enzymes can be characterized as metalloenzymes, while currently only 7% of FDA-approved drugs in the United States target this class of protein. This is despite the fact that there are many dozens of already identified metalloenzyme targets involved in virtually every therapeutic area, including anti-inflammatory, antibiotics, antivirals, an ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Treatment of status epilepticus and refractory status epilepticus with intravenous topiramate.

    SBC: PREVEP, LLC            Topic: NINDS

    Abstract Status epilepticus (SE) is a common neurologic emergency that fails to respond to first- and second-line anti-seizure medications (ASMs) in about one third of instances, thus progressing to refractory SE (RSE). Patients with RSE are at grave risk for neurological morbidity and mortality. The recently completed NIH-funded Established SE Treatment Trial (ESETT) highlights the need for impro ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Simple and Accessible Microfluidic Platform for Single Molecule Sequence Profiling of Tumor-derived DNA within Liquid Biopsies

    SBC: HYPERMELT, LLC            Topic: 394

    Project Summary/ Abstract Over 600,000 people in the US will die from cancer this year. It is estimated that 25% of these deaths could have been prevented by detection in earlier stages. Implementation of minimally-invasive routine screening, such as pap smears for cervical cancer, has proven to be an effective approach for reducing cancer mortality. However, several challenges prevent successful ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Staph Aureus Vaccine

    SBC: BIOLOGICAL MIMETICS, INC.            Topic: NIAID

    Abstract Methicillin-resistant Staphylococcus aureus is often considered the prototype hospital-acquired infection. In spite of the billions of dollars spent on preventive measures, estimates of the incidence are in the hundreds of thousands, with tens of thousands of people per year succumbing to disease in the USA alone. Prophylactic vaccines against S. aureus would have an enormous impact in th ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Extraction of Vital Signs using a Telehealth Application for Asthma- EViTA-AThe purpose of this grant is to evaluate mobile devices to extract vitals signs to monitor patients with Asthma

    SBC: M5 ENTERPRISE LLC            Topic: NHLBI

    Asthma is a chronic disease that affects quality of life, productivity, and healthcare use, and can ultimately lead to death. The costs of asthma are largely due to uncontrolled disease and accordingly rise as its prevalence and severity increase. Unfortunately, the incidence and impact of asthma attacks have not improved despite widespread adoption of effective universal treatment guidelines by h ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Rapid Microbial ID Direct From Specimen

    SBC: PATAIGIN LLC            Topic: NIAID

    Abstract This proposal is for BACLIB, a cost-effective, one hour microbial ID test direct from a clinical specimen or positive blood culture. Microbial ID testing is an essential step to appropriate antimicrobial treatment. Today, positive microbial culture indicates a microbial infection, and subsequent microbial ID testing on cultured samples identifies species. Microbial cultures typically take ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Development of optimized adeno-associated viral capsids for muscle gene therapy

    SBC: AAVOGEN INC            Topic: NIAMS

    PROJECT SUMMARY. Gene therapeutics offer hope to many patients with rare muscle and neuromuscular diseases. Despite some early successes, several serious off-target safety concerns have compromised their development due to hepatic toxicities and related immune responses to the adeno-associated viral (AAV) vectors. The generation of novel capsids with superior muscle specificity could, therefore, r ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government